Vaxcyte, INC Form 4 insider transactions

Vaxcyte's CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan on July 18, 2024.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold 5,000 shares of common stock at $85 per share on July 16, 2024, under a pre-arranged 10b5-1 trading plan.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., reports the sale of 5,000 shares of common stock at $80 per share on July 8, 2024, following the exercise of stock options.

Director John Furey acquired 16,760 stock options in Vaxcyte, Inc. on July 2, 2024.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reported the exercise of stock options and subsequent sale of common stock on July 1, 2024, according to a Form 4 filing with the SEC.

Vaxcyte's Chief Operating Officer, Jim Wassil, executed multiple sales of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares on June 18, 2024, according to a Form 4 filing with the SEC.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports the disposition of 335 common stock shares to cover tax withholding obligations.

Director Jacks Lee reports acquisition of 1,550 shares of common stock and 7,250 stock options in Vaxcyte, Inc.

Director Teri Loxam reports acquisition of common stock and stock options in Vaxcyte, Inc.

Director Halley E. Gilbert reports acquisition of common stock and stock options in Vaxcyte, Inc.

Director Heath Lukatch reports acquisition of stock options and restricted stock units in Vaxcyte, Inc.

Director Anne S. Drapeau reports acquisition of stock and option awards in Vaxcyte, Inc.

Director Peter Hirth of Vaxcyte, Inc. reports acquisition of restricted stock units and stock options, along with adjustments to existing holdings, in a Form 4 filing with the SEC.

Director Carlos V. Paya of Vaxcyte, Inc. reports acquisition and disposal of common stock and stock options.

Director Halley Gilbert exercised stock options and sold shares of Vaxcyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports the acquisition and disposal of common stock and derivative securities.

Vaxcyte's Chief Operating Officer, Jim Wassil, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on May 20, 2024, according to a Form 4 filing with the SEC.

Mikhail Eydelman, SVP, General Counsel & Corp Sec of Vaxcyte, Inc., reported the sale of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, executed stock sales under a pre-arranged 10b5-1 trading plan and transferred shares to his ex-spouse as part of a divorce settlement.

Vaxcyte CEO Grant Pickering sold shares of the company's common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold 15,000 shares of common stock on April 23, 2024, according to a Form 4 filing with the SEC.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and acquired 3,551 shares of common stock on April 17, 2024.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares on April 1, 2024, according to a Form 4 filing with the SEC.